Elvstam, OlofMalmborn, KasperElen, SixtenMarrone, GaetanoGarcia, FedericoZazzi, MaurizioSönnerborg, AndersBöhm, MichaelSeguin-Devaux, CaroleBjörkman, Per2023-05-032023-05-03202-09-05Elvstam O, Malmborn K, Elén S, Marrone G, García F, Zazzi M, et al. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort. Clin Infect Dis. 2023 Jan 6;76(1):25-31.http://hdl.handle.net/10668/19738It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral load (VL) of People with HIV-1 who started ART in 2005 or later were identified from the EuResist Integrated Database. We analyzed the incidence of VF (≥200 copies/mL) depending on viremia exposure, starting 12 months after ART initiation (grouped as suppression [≤50 copies/mL], blips [isolated VL of 51-999 copies/mL], and LLV [repeated VLs of 51-199 copies/mL]) using Cox proportional hazard models adjusted for age, sex, injecting drug use, pre-ART VL, CD4 count, HIV-1 subtype, type of ART, and treatment experience. We queried the database for drug-resistance mutations (DRM) related to episodes of LLV and VF and compared those with baseline resistance data. During 81 837 person-years of follow-up, we observed 1424 events of VF in 22 523 participants. Both blips (adjusted subhazard ratio [aHR], 1.7; 95% confidence interval [CI], 1.3-2.2) and LLV (aHR, 2.2; 95% CI, 1.6-3.0) were associated with VF, compared with virologic suppression. These associations remained statistically significant in subanalyses restricted to people with VL Both blips and LLV during ART are associated with increased risk of subsequent VF.enAttribution-NonCommercial 4.0 Internationalhttps://creativecommons.org/licenses/by-nc/4.0/HIV-1low-level viremiatreatment failureviral blipsHumansAnti-HIV AgentsViremiaTreatment FailureHIV InfectionsAntiretroviral Therapy, Highly ActiveViral Loadresearch article36100984open accessCarga viralFármacos anti-VIHHumanosInfecciones por VIHInsuficiencia del tratamientoTerapia antirretroviral altamenteActivaViremia10.1093/cid/ciac7621537-6591PMC9825828https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825828https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825828/pdf